Literature DB >> 26828765

Resisting resistance: Establishing new treatment options for CRPC patients.

Shaunna Beedie1, William D Figg1.   

Abstract

Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.

Entities:  

Keywords:  abiraterone; enzalutamide; prostate cancer; ▵4-abiraterone

Mesh：

Year:  2016        PMID： 26828765      PMCID： PMC4910910          DOI： 10.1080/15384047.2016.1139271

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  6 in total

1.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

2.  Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.

Authors:  Gang Wu; Shengsong Huang; Kent L Nastiuk; Jinliang Li; Jun Gu; Ming Wu; Qimin Zhang; Hanqing Lin; Denglong Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

3.  Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

Authors:  S E Barrie; G A Potter; P M Goddard; B P Haynes; M Dowsett; M Jarman
Journal:  J Steroid Biochem Mol Biol       Date:  1994-09       Impact factor: 4.292

4.  Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.

Authors:  G A Potter; S E Barrie; M Jarman; M G Rowlands
Journal:  J Med Chem       Date:  1995-06-23       Impact factor: 7.446

Review 5.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Authors:  Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs
Journal:  Eur Urol       Date:  2014-10-08       Impact factor: 20.096

6.  Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

Authors:  Zhenfei Li; Andrew C Bishop; Mohammad Alyamani; Jorge A Garcia; Robert Dreicer; Dustin Bunch; Jiayan Liu; Sunil K Upadhyay; Richard J Auchus; Nima Sharifi
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.